Dendritic Cell-based Immunotherapy in Mesothelioma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
Exploiting the immunostimulatory capacities of dendritic cells holds great promise for cancer immunotherapy. A mouse model for malignant mesothelioma allowed us to prove that autologous dendritic cells presenting tumor antigens were very effective by (partly) inhibiting tumor growth. This study will test the feasibility and safety of a clinical trial using autologous DC as a therapeutic adjuvant for the treatment of malignant pleural mesothelioma.
Epistemonikos ID: ce6cc14b4cf411731901cf1b21f1c9ce0f01a992
First added on: May 04, 2024